Table 3 Univariable and multivariable analysis of pooled data

From: Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women

Covariates at diagnosis

Univariable

Multivariable

HR (95% CI)

P univariable

Events/cases

HR (95% CI)

P multivariable

Model 1 (DFS early onset)

rs715212

1.28 (1.14–1.43)

1.94 × 10−5

698/2293

1.38 (1.23–1.56)

5.37 × 10−8

ER status

0.78 (0.67–0.91)

0.001

702/2295

1.09 (0.90–1.31)

0.377

Grade

1.53 (1.33–1.75)

1.92 × 10−9

684/2260

1.37 (1.17–1.61)

9.05 × 10−5

Tumour size (mm)

1.02 (1.01–1.02)

1.00 × 10−13

667/2258

1.01 (1.01–1.02)

1.01 × 10−13

Nodal status

2.54 (2.16–3.00)

1.00 × 10−13

676/2271

2.37 (1.98–2.83)

1.00 × 10−13

Cohort

0.63 (0.59–0.67)

1.00 × 10−13

705/2315

0.62 (0.58–0.67)

1.00 × 10−13

Model 2 (DFS early onset)

rs10963755

1.21 (1.09–1.36)

0.00065

689/2286

1.27 (1.13–1.43)

4.51 × 10−5

ER status

0.78 (0.67–0.91)

0.00117

702/2295

1.10 (0.92–1.33)

0.301

Grade

1.53 (1.33–1.75)

1.92 × 10−9

684/2260

1.38 (1.18–1.62)

7.33 × 10−5

Tumour size (mm)

1.02 (1.01–1.02)

1.00 × 10−13

667/2258

1.01 (1.01–1.02)

1.00 × 10−13

Nodal status

2.54 (2.16–3.00)

1.00 × 10−13

676/2271

2.31 (1.93–2.77)

1.00 × 10−13

Cohort

0.63 (0.59–0.67)

1.00 × 10−13

705/2315

0.63 (0.58–0.68)

1.00 × 10−13

Model 3 (DFS all cases)

rs12302097

1.28 (1.13–1.46)

1.65 × 10−4

1312/5825

1.26 (1.10–1.44)

0.001

ER status

0.66 (0.59–0.74)

7.11 × 10−13

1298/5756

0.80 (0.70–0.91)

0.001

Grade

1.50 (1.37–1.65)

1.00 × 10−13

1261/5695

1.56 (1.40–1.73)

1.01 × 10−13

Tumour size (mm)

1.02 (1.02–1.02)

1.00 × 10−13

1256/5711

1.02 (1.01–1.02)

1.00 × 10−13

Nodal status

1.98 (1.75–2.24)

1.00 × 10−13

1274/5747

2.10 (1.84–2.41)

1.00 × 10−13

Cohort

0.61 (0.58–0.64)

1.00 × 10−13

1316/5840

0.58 (0.55–0.62)

1.00 × 10−13

Model 4 (OS all cases)

rs410155

1.20 (1.04–1.39)

0.0154

1063/5945

1.28 (1.09–1.51)

0.0023

ER status

0.60 (0.53–0.68)

1.00 × 10−13

1081/5919

0.66 (0.57–0.77)

5.92 × 10−8

Grade

1.72 (1.54–1.91)

1.00 × 10−13

990/5692

1.65 (1.46–1.87)

1.06 × 10−13

Tumour size (mm)

1.02 (1.02–1.02)

1.00 × 10−13

981/5708

1.02 (1.02–1.02)

1.00 × 10−13

Nodal status

2.12 (1.85–2.44)

1.00 × 10−13

998/5744

2.22 (1.90–2.59)

1.00 × 10−13

Cohort

0.79 (0.76–0.83)

1.00 × 10−13

1101/6039

0.67 (0.63–0.71)

1.00 × 10−13

  1. Univariable and multivariable analyses were performed with pooled data from ABCFS, HEBCS, POSH (stages 1 and 2) and SUCCESS-A for overall survival (OS). The ABCFS cohort was excluded from the analysis of disease-free survival (DFS). For univariate analyses, the number of events and cases is slightly different for each covariate due to variation in the number of cases with missing data. For multivariable analyses, the following number of events and cases were used: model 1: 642/2172, model 2: 634/2166, model 3: 1201/5538, model 4: 911/5482. In each model the hazard ratios (HRs) and 95% confidence interval (CI) were adjusted for oestrogen receptor status (ER), grade, maximum tumour size, nodal status, SNP and cohort. P univariable, P-values from univariable Cox regression; P multivariable, P-values from multivariable Cox regression.
Back to article page